Literature DB >> 24634494

Innate PI3K p110δ regulates Th1/Th17 development and microbiota-dependent colitis.

Erin C Steinbach1, Taku Kobayashi, Steven M Russo, Shehzad Z Sheikh, Gregory R Gipson, Samantha T Kennedy, Jennifer K Uno, Yoshiyuki Mishima, Luke B Borst, Bo Liu, Hans Herfarth, Jenny P Y Ting, R Balfour Sartor, Scott E Plevy.   

Abstract

The p110δ subunit of class IA PI3K modulates signaling in innate immune cells. We previously demonstrated that mice harboring a kinase-dead p110δ subunit (p110δ(KD)) develop spontaneous colitis. Macrophages contributed to the Th1/Th17 cytokine bias in p110δ(KD) mice through increased IL-12 and IL-23 expression. In this study, we show that the enteric microbiota is required for colitis development in germfree p110δ(KD) mice. Colonic tissue and macrophages from p110δ(KD) mice produce significantly less IL-10 compared with wild-type mice. p110δ(KD) APCs cocultured with naive CD4+ Ag-specific T cells also produce significantly less IL-10 and induce more IFN-γ- and IL-17A-producing CD4+ T cells compared with wild-type APCs. Illustrating the importance of APC-T cell interactions in colitis pathogenesis in vivo, Rag1(-/-)/p110δ(KD) mice develop mild colonic inflammation and produced more colonic IL-12p40 compared with Rag1(-/-) mice. However, CD4+ CD45RB(high/low) T cell Rag1(-/-)/p110δ(KD) recipient mice develop severe colitis with increased percentages of IFN-γ- and IL-17A-producing lamina propria CD3+D4+ T cells compared with Rag1(-/-) recipient mice. Intestinal tissue samples from patients with Crohn's disease reveal significantly lower expression of PIK3CD compared with intestinal samples from non-inflammatory bowel disease control subjects (p < 0.05). PIK3CD expression inversely correlates with the ratio of IL12B:IL10 expression. In conclusion, the PI3K subunit p110δ controls homeostatic APC-T cell interactions by altering the balance between IL-10 and IL-12/23. Defects in p110δ expression and/or function may underlie the pathogenesis of human inflammatory bowel disease and lead to new therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24634494      PMCID: PMC3992276          DOI: 10.4049/jimmunol.1301533

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  44 in total

Review 1.  The impact of the microbiota on the pathogenesis of IBD: lessons from mouse infection models.

Authors:  Sandra Nell; Sebastian Suerbaum; Christine Josenhans
Journal:  Nat Rev Microbiol       Date:  2010-07-12       Impact factor: 60.633

2.  Glycogen synthase kinase 3-β: a master regulator of toll-like receptor-mediated chronic intestinal inflammation.

Authors:  Claudia Hofmann; Nadja Dunger; Jürgen Schölmerich; Werner Falk; Florian Obermeier
Journal:  Inflamm Bowel Dis       Date:  2010-11       Impact factor: 5.325

Review 3.  The role of the macrophage in sentinel responses in intestinal immunity.

Authors:  Shehzad Z Sheikh; Scott E Plevy
Journal:  Curr Opin Gastroenterol       Date:  2010-11       Impact factor: 3.287

4.  Altered macrophage function contributes to colitis in mice defective in the phosphoinositide-3 kinase subunit p110δ.

Authors:  Jennifer K Uno; Kavitha N Rao; Katsuyoshi Matsuoka; Shehzad Z Sheikh; Taku Kobayashi; Fengling Li; Erin C Steinbach; Antonia R Sepulveda; Bart Vanhaesebroeck; R Balfour Sartor; Scott E Plevy
Journal:  Gastroenterology       Date:  2010-07-14       Impact factor: 22.682

Review 5.  Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function.

Authors:  Maria T Abreu
Journal:  Nat Rev Immunol       Date:  2010-02       Impact factor: 53.106

6.  The TSC-mTOR signaling pathway regulates the innate inflammatory response.

Authors:  Thomas Weichhart; Giuseppina Costantino; Marko Poglitsch; Margit Rosner; Maximilian Zeyda; Karl M Stuhlmeier; Thomas Kolbe; Thomas M Stulnig; Walter H Hörl; Markus Hengstschläger; Mathias Müller; Marcus D Säemann
Journal:  Immunity       Date:  2008-10-09       Impact factor: 31.745

Review 7.  The multiple facets of mTOR in immunity.

Authors:  Thomas Weichhart; Marcus D Säemann
Journal:  Trends Immunol       Date:  2009-04-08       Impact factor: 16.687

8.  ATP drives lamina propria T(H)17 cell differentiation.

Authors:  Koji Atarashi; Junichi Nishimura; Tatsuichiro Shima; Yoshinori Umesaki; Masahiro Yamamoto; Masaharu Onoue; Hideo Yagita; Naoto Ishii; Richard Evans; Kenya Honda; Kiyoshi Takeda
Journal:  Nature       Date:  2008-08-20       Impact factor: 49.962

9.  Phosphoinositide 3-kinase δ regulates membrane fission of Golgi carriers for selective cytokine secretion.

Authors:  Pei Ching Low; Ryo Misaki; Kate Schroder; Amanda C Stanley; Matthew J Sweet; Rohan D Teasdale; Bart Vanhaesebroeck; Frédéric A Meunier; Tomohiko Taguchi; Jennifer L Stow
Journal:  J Cell Biol       Date:  2010-09-13       Impact factor: 10.539

10.  TPL-2 negatively regulates interferon-beta production in macrophages and myeloid dendritic cells.

Authors:  Frank Kaiser; Dorthe Cook; Stamatia Papoutsopoulou; Ricardo Rajsbaum; Xuemei Wu; Huei-Ting Yang; Susan Grant; Paola Ricciardi-Castagnoli; Philip N Tsichlis; Steven C Ley; Anne O'Garra
Journal:  J Exp Med       Date:  2009-08-10       Impact factor: 14.307

View more
  26 in total

Review 1.  The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.

Authors:  Adrian Wiestner
Journal:  Haematologica       Date:  2015-12       Impact factor: 9.941

2.  Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+ CD45RB high T Cells into Immunodeficient Mice.

Authors:  Erin C Steinbach; Gregory R Gipson; Shehzad Z Sheikh
Journal:  J Vis Exp       Date:  2015-04-21       Impact factor: 1.355

Review 3.  The biology behind PI3K inhibition in chronic lymphocytic leukaemia.

Authors:  Valentín Ortiz-Maldonado; Marcial García-Morillo; Julio Delgado
Journal:  Ther Adv Hematol       Date:  2015-02

Review 4.  PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.

Authors:  Benjamin L Lampson; Jennifer R Brown
Journal:  Expert Opin Investig Drugs       Date:  2017-10-06       Impact factor: 6.206

Review 5.  Emerging role of BCR signaling inhibitors in immunomodulation of chronic lymphocytic leukemia.

Authors:  Kamira Maharaj; Eva Sahakian; Javier Pinilla-Ibarz
Journal:  Blood Adv       Date:  2017-09-26

6.  Profile of Dennis L. Kasper.

Authors:  Jennifer Viegas
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-02       Impact factor: 11.205

7.  Microbiota maintain colonic homeostasis by activating TLR2/MyD88/PI3K signaling in IL-10-producing regulatory B cells.

Authors:  Yoshiyuki Mishima; Akihiko Oka; Bo Liu; Jeremy W Herzog; Chang Soo Eun; Ting-Jia Fan; Emily Bulik-Sullivan; Ian M Carroll; Jonathan J Hansen; Liang Chen; Justin E Wilson; Nancy C Fisher; Jenny Py Ting; Tomonori Nochi; Angela Wahl; J Victor Garcia; Christopher L Karp; R Balfour Sartor
Journal:  J Clin Invest       Date:  2019-06-18       Impact factor: 14.808

8.  PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression.

Authors:  Shuai Dong; Bonnie K Harrington; Eileen Y Hu; Joseph T Greene; Amy M Lehman; Minh Tran; Ronni L Wasmuth; Meixiao Long; Natarajan Muthusamy; Jennifer R Brown; Amy J Johnson; John C Byrd
Journal:  J Clin Invest       Date:  2018-11-19       Impact factor: 14.808

9.  Phosphatidylinositol 3-Kinase p110δ Isoform Regulates CD8+ T Cell Responses during Acute Viral and Intracellular Bacterial Infections.

Authors:  Donald T Gracias; Alina C Boesteanu; Joseph A Fraietta; Jennifer L Hope; Alison J Carey; Yvonne M Mueller; Omkar U Kawalekar; Adam J Fike; Carl H June; Peter D Katsikis
Journal:  J Immunol       Date:  2016-01-06       Impact factor: 5.422

10.  Human primary immunodeficiency caused by expression of a kinase-dead p110δ mutant.

Authors:  Sarah Beaussant Cohen; Wayne Bainter; Jared L Johnson; Ting-Yu Lin; Jenny C Y Wong; Jacqueline G Wallace; Jennifer Jones; Sonia Qureshi; Fatima Mir; Farah Qamar; Lewis C Cantley; Raif S Geha; Janet Chou
Journal:  J Allergy Clin Immunol       Date:  2018-10-16       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.